US009408908B2

(12) **United States Patent**
van den Hurk et al.

(10) **Patent No.: US 9,408,908 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **COMBINATION ADJUVANT FORMULATION**

(71) Applicants: **University of Saskatchewan**, Saskatoon (CA); **The University of British Columbia**, Vancouver (CA); **Dalhousie University**, Halifax (CA); **International Vaccine Institute**, Gwanak-Gu, Seoul (KR)

(72) Inventors: **Sylvia van den Hurk**, Saskatoon (CA); **Volker Gerdts**, Saskatoon (CA); **Andrew Potter**, Saskatoon (CA); **Lorne Babiuk**, Edmonton (CA); **Robert Hancock**, Vancouver (CA); **Scott Halperin**, Halifax (CA); **Jennifer Kovacs-Nolan**, Guelph (CA); **George Mutwiri**, Saskatoon (CA); **Song Lee**, Halifax (CA); **Mi-Na Kweon**, Seoul (KR); **Jason Kindrachuk**, Vancouver (CA); **Melissa Elliott**, Vancouver (CA)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 40 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/768,694**

(22) Filed: **Feb. 15, 2013**

(65) **Prior Publication Data**

US 2014/0248313 A1 Sep. 4, 2014

Related U.S. Application Data

(62) Division of application No. 12/587,955, filed on Oct. 15, 2009, now Pat. No. 9,061,001.

(60) Provisional application No. 61/196,226, filed on Oct. 16, 2008.

(51) **Int. Cl.**

A61K 39/39	(2006.01)
A61K 39/12	(2006.01)
A61K 47/30	(2006.01)
A61K 45/06	(2006.01)
A61K 39/155	(2006.01)
C07K 7/08	(2006.01)
A61K 39/02	(2006.01)
A61K 39/00	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/39*** (2013.01); ***A61K 39/099*** (2013.01); ***A61K 39/12*** (2013.01); ***A61K 39/155*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/30*** (2013.01); ***C07K 7/08*** (2013.01); *A61K 2039/55516* (2013.01); *A61K 2039/55561* (2013.01); *A61K 2039/6093* (2013.01); *C12N 2760/18534* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,494,673	A	2/1996	Andrianov
5,500,161	A	3/1996	Andrianov
5,529,777	A	6/1996	Andrianov
5,562,909	A	10/1996	Allcock
5,760,271	A	6/1998	Andrianov
5,855,895	A	1/1999	Andrianov
5,891,444	A	4/1999	Jenkins
6,194,388	B1	2/2001	Krieg
6,207,646	B1	3/2001	Krieg
6,214,806	B1	4/2001	Krieg
6,218,371	B1	4/2001	Krieg
6,239,116	B1	5/2001	Krieg
6,339,068	B1	1/2002	Krieg
6,921,535	B2 *	7/2005	Buchholz et al. 424/211.1
7,169,395	B1	1/2007	Cates
9,061,001	B2 *	6/2015	van Drunen Littel-van den Hurk A61K 39/099
2003/0139364	A1	7/2003	Krieg
2005/0244505	A1	11/2005	Higbee et al.
2008/0237905	A1	10/2008	Andrianov
2009/0186050	A1 *	7/2009	Fouchier et al. 424/211.1

FOREIGN PATENT DOCUMENTS

WO	WO 95/02628	1/1995
WO	0115727	3/2001
WO	0122990	4/2001
WO	03015711	2/2003
WO	WO 03/030934	4/2003
WO	2006050611	5/2006
WO	2008022444	2/2008

OTHER PUBLICATIONS

Mutwiri et al., Innate Immunity and New Adjuvants, 2007, Rev. sci. tech. Off. int. Epiz., vol. 26, No. 1, pp. 147-156.*

Biragyn, "Defensins-Non-Antibiotic Use for Vaccine Development," Current Protein and Peptide Science, 6:53-60 (2005).

Kindrachuk, et al., "A Novel Vaccine Adjuvant Comprised of a Synthetic Innate Defence Regulator Peptide and CPG Oligonucleotide Links Innate and Adaptive Immunity," Vaccine, 27:4662-4671 (2009).

Andrianov et al., Synthesis, Properties and Biological Activity of Poly[di(sodium carboxylatoethylphenoxy)phosphazene], 2006, Biomacromolecules, vol. 7, pp. 394-399.

(Continued)

Primary Examiner — Benjamin P Blumel

(74) *Attorney, Agent, or Firm* — Roberta L. Robins; Robins Law Group

(57) **ABSTRACT**

Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.

40 Claims, 28 Drawing Sheets